Skin Antisepsis before Surgical Fixation of Extremity Fractures

Authors

Sheila Sprague, McMaster University
Gerard Slobogean, University of Maryland School of Medicine
Jeffrey L. Wells, University of Maryland Baltimore
Nathan N. O'Hara, University of Maryland School of Medicine
Lehana Thabane, McMaster University
C Daniel Mullins, University of Maryland School of Pharmacy
Anthony D. Harris, University of Maryland School of Medicine
Amber Wood, Association of periOperative Registered Nurses, Denver
Darius Viskontas, University of British Columbia, Vancouver
Kelly L. Apostle, University of British Columbia, Vancouver
Robert V. O'Toole, University of Maryland Baltimore
Manjari Joshi, University of Maryland Baltimore
Herman Johal, McMaster University
Jamal Al-Asiri, McMaster University
Robert A. Hymes, Inova Fairfax Medical Campus, Fairfax, VA
Greg E. Gaski, Inova Fairfax Medical Campus, Fairfax, VA
Holly T. Pilson, Wake Forest University School of Medicine, Winston-Salem, NC
Eben A. Carroll, Wake Forest University School of Medicine, Winston-Salem, NC
Sharon Babcock, Wake Forest University School of Medicine, Winston-Salem, NC
Jason J. Halvorson, Wake Forest University School of Medicine, Winston-Salem, NC
Nicholas M. Romeo, MetroHealth Medical Center, Cleveland , OH
Christopher A. Matson, MetroHealth Medical Center, Cleveland, OH
Thomas F. Higgins, University of Utah, Salt Lake City, UT
Lucas S. Marchand, University of Utah, Salt Lake City, UT
Patrick F. Bergin, University of Mississippi Medical Center, Jackson, MS
John Morellato, University of Mississippi Medical Center, Jackson, MS
Robert E. Van Demark III, Sanford Health USD Medical Center, Sioux Falls, SD
G David Potter, Northwest Texas Healthcare System, Amarillo , TX
Robert D. Zura, LSU Health Sciences Center - New OrleansFollow
et al

Document Type

Article

Publication Date

2-1-2024

Publication Title

The New England Journal of Medicine

Abstract

BACKGROUND: Studies evaluating surgical-site infection have had conflicting results with respect to the use of alcohol solutions containing iodine povacrylex or chlorhexidine gluconate as skin antisepsis before surgery to repair a fractured limb (i.e., an extremity fracture). METHODS: In a cluster-randomized, crossover trial at 25 hospitals in the United States and Canada, we randomly assigned hospitals to use a solution of 0.7% iodine povacrylex in 74% isopropyl alcohol (iodine group) or 2% chlorhexidine gluconate in 70% isopropyl alcohol (chlorhexidine group) as preoperative antisepsis for surgical procedures to repair extremity fractures. Every 2 months, the hospitals alternated interventions. Separate populations of patients with either open or closed fractures were enrolled and included in the analysis. The primary outcome was surgical-site infection, which included superficial incisional infection within 30 days or deep incisional or organ-space infection within 90 days. The secondary outcome was unplanned reoperation for fracture-healing complications. RESULTS: A total of 6785 patients with a closed fracture and 1700 patients with an open fracture were included in the trial. In the closed-fracture population, surgical-site infection occurred in 77 patients (2.4%) in the iodine group and in 108 patients (3.3%) in the chlorhexidine group (odds ratio, 0.74; 95% confidence interval [CI], 0.55 to 1.00; P = 0.049). In the open-fracture population, surgical-site infection occurred in 54 patients (6.5%) in the iodine group and in 60 patients (7.3%) in the chlorhexidine group (odd ratio, 0.86; 95% CI, 0.58 to 1.27; P = 0.45). The frequencies of unplanned reoperation, 1-year outcomes, and serious adverse events were similar in the two groups. CONCLUSIONS: Among patients with closed extremity fractures, skin antisepsis with iodine povacrylex in alcohol resulted in fewer surgical-site infections than antisepsis with chlorhexidine gluconate in alcohol. In patients with open fractures, the results were similar in the two groups. (Funded by the Patient-Centered Outcomes Research Institute and the Canadian Institutes of Health Research; PREPARE ClinicalTrials.gov number, NCT03523962.).

First Page

409

Last Page

420

PubMed ID

38294973

Volume

390

Issue

5

Comments

See article for full author list and author affiliations.

Share

COinS